

CORRECTION

Correction: Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD

Megha Verma, David Beaulieu-Abdelahad, Ghania Ait-Ghezala, Rena Li, Fiona Crawford, Michael Mullan, Daniel Paris

The following information is missing from the Funding section: This study was also funded by the Roskamp Foundation.

Reference

1. Verma M, Beaulieu-Abdelahad D, Ait-Ghezala G, Li R, Crawford F, Mullan M, et al. (2015) Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD. PLoS ONE 10(5): e0128224. doi: [10.1371/journal.pone.0128224](https://doi.org/10.1371/journal.pone.0128224) PMID: [26010758](https://pubmed.ncbi.nlm.nih.gov/26010758/)



OPEN ACCESS

Citation: Verma M, Beaulieu-Abdelahad D, Ait-Ghezala G, Li R, Crawford F, Mullan M, et al. (2015) Correction: Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD. PLoS ONE 10(7): e0134776. doi:10.1371/journal.pone.0134776

Published: July 31, 2015

Copyright: © 2015 Verma et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.